The user is pleased with their hair transplant results after six months and seeks feedback. The conversation is positive, with others affirming the success of the procedure.
The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."
Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.
The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.
GHK-Cu injections led to unexpected temple hair growth for someone who had been using minoxidil and finasteride for over a decade. The user plans to continue using GHK-Cu and experiment with a DIY AHK-Cu serum.
A 33-year-old man experienced diffuse thinning and hair shedding due to sleep deprivation and low testosterone. After starting hCG treatment, he noticed hair regrowth on his temples.
AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.
Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.
The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
The user is using a topical solution with finasteride, minoxidil, and tretinoin and is considering adding GHK-Cu to enhance hair growth and quality. Another user suggests diluting GHK-Cu and storing it in a smaller, refrigerated bottle.
Cyproterone Acetate stopped hair loss and led to regrowth on the temples for a transgender individual, which is considered a good sign. Unlike Minoxidil and Finasteride, which can cause initial shedding, Cyproterone did not cause shedding.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.
A 35-year-old had a hair transplant with 3,153 grafts at HLC Ankara, experiencing some pain and numbness but pleased with the density and results. The procedure cost $10,000, and the user has been using finasteride for over 13 years.
The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.
The user is expressing an obsession with hair loss and spends all their time researching and discussing it. Other users suggest seeking therapy and focusing on other aspects of life.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.
GHK-Cu serums for hair growth have mixed results, with some users not seeing significant benefits. Users have tried various brands like Tricomin and Actifolic without success.
GHK-CU is not considered as effective for hair loss as finasteride, minoxidil, or RU58841, with many users reporting minimal benefits. Some users experienced skin improvements, but its impact on hair is debated and often attributed to concurrent use of other treatments.